Haijun Dong – CEO, BioDuro-Sundia
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world,…
Address: Guilinyang Develops Area, Haikou, Hainan province, P.R.China 571127
Tel: +86 898 6571 8261
Hainan Yishun Pharmaceutical Co,. Ltd is a modern large pharmaceutical enterprise, which is established in Jun 6, 2003, with a registered capital of 50 million RMB (about 7.8 million dollars) and fixed asserts of 100 million RMB (about 15.7 million dollars). Company is located in Guilinyang Develops Area, Haikou, Hainan province, P.R.China. The plant area is more than 12,000 square meters, with a staff of more than 200. There are several production lines: powder for injection, new-type solid dosage form, APIs, small capacity injection and lyophilized powder for injection. All the production lines, staff and facility are organized and built strictly by GMP standard, and pass through and obtain new version SFDA-GMP certificate. On the aspect of quality control and quality assurance, we start with a high standard to build new plants, to introduce advanced production equipments, to be equipped with state-level drug quality testing instruments. All the efforts we make are to establish a comprehensive quality control and quality assurance system to supervise every link of drug production, sale and recall to ensure product quality. The whole process is in strict accordance with GMP requirements to implement and manage.
For overseas market, we will focus on promoting products of lyophilized powder for injection and sterile powder for injection. There is a products catalog available for international registration and sale. The overseas target markets of the company are Southeast Asia, Africa and Latin America. The company is looking for long-term partners and agents to create business opportunities and to achieve a win-win situation.
Dr Haijun Dong, recently appointed CEO of BioDuro-Sundia, shares his priorities for the newly merged entity, one of the largest Contract Research, Development and Manufacturing organizations (CRDMOs) in the world,…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into rare disease public insurance coverage across key…
The latest from Chinese pharma, including a new deal between AstraZeneca and Junshi Biosciences; Innoforce and dMed’s R&D collab; and investment news on Clover Biopharmaceuticals, Sciwind Biosciences, and Gensciences. …
One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province,…
HiFiBiO Therapeutics cofounder, CEO and CSO Dr Liang Schweizer fits the profile of a Chinese biotech CEO to a T: advanced degrees in different scientific fields, including a master’s in…
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for Drug Evaluation & Inspection analyse…
Dr Liang Schweizer introduces immunotherapy-focused biotech HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other…
Eric Bouteiller examines the most recent update to China’s National Reimbursement Drug List, the positive impact that a de facto annual review has had on drug approval timelines, and why…
Since China first announced its ground-breaking volume-based procurement (VBP) pilot program to reduce drug expenditures in 2018, the world’s second-largest pharma market has steadily expanded the 4+7 pilot program into…
2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back…
Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you profiles of the seven biggest biotech companies to IPO in 2020. Notably, six…
The latest from Chinese pharma, including domestic regulatory approval for Sinopharm’s COVID-19 vaccine, how the country’s online healthcare industry is booming in the wake of the pandemic, and news that…
See our Cookie Privacy Policy Here
